About Careers Internship MedBlog Contact us

Clinical Trial Shows Genetically Modified Herpes Virus Effective Against Skin Cancer

by Shirley Johanna on May 27, 2015 at 7:03 PM
Font : A-A+

Clinical Trial Shows Genetically Modified Herpes Virus Effective Against Skin Cancer

A genetically modified herpes virus has been used to successfully treat skin cancer by destroying cancer cells and triggering an immune response, says a new research.

It was the first time an advanced-stage trial of this type of drug has shown such positive results, according to scientists from The Institute of Cancer Research in London who published their study in the American Journal of Clinical Oncology.


The dramatic results, showing a large jump in survival length, could lead the drug T-VEC (Talimogene Laherparepvec) to be approved by US and European drug regulators.

Researchers randomly selected 436 patients with inoperable advanced melanoma to receive an injection of T-VEC made by US company Amgen. In the study, more than 16% of those treated with the drug had a treatment response lasting longer than six months, compared with two percent in the control groups.

Some patients have been in remission for more than three years, the study said. Results were more pronounced in patients with less advanced skin cancer and in those who had no prior treatment, indicating T-VEC could be a first-line treatment. Among 163 patients with less advanced melanoma, people treated with T-VEC survived an average of 41 months compared to 21.5 months for 66 patients treated with other therapy.

"There is increasing excitement over the use of viral treatments like T-VEC for cancer, because they can launch a two-pronged attack on tumors - both killing cancer cells directly and marshaling the immune system against them," said Kevin Harrington from The Institute of Cancer Research.

The drug uses a version of the herpes virus with two key genes removed to prevent it from affecting healthy cells, the scientists said.

Source: Medindia


Recommended Readings

Latest Cancer News

Combination Therapy may Benefit Leukemia Patients
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
 Myelofibrosis: New Drugs to Revolutionize Treatment
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
 Blood Vessels Can Kill Cancer Cells and Stop Breast Cancer Spread
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
 Weed Killer Agent Orange May Increase the Risk of Blood Cancer Among Veterans
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Two Years: Optimal Duration of Immunotherapy in Advanced Lung Cancer
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Clinical Trial Shows Genetically Modified Herpes Virus Effective Against Skin Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests